Stem Cell Therapy in Switzerland: What Is Legal and What the Evidence Shows

Stem cell therapy in Switzerland: two treatments under one name

Stem cell therapy in Switzerland means two different things. One is haematopoietic stem cell transplantation, the blood stem cell transplant used for leukaemia, lymphoma, myeloma and some inherited blood and immune disorders, which basic insurance pays for in accredited centres. The other is the injection of cells from fat, bone marrow or donor tissue into joints, skin or the bloodstream, which remains experimental and, once the cells are substantially processed or put to a new use, needs Swissmedic authorisation or an approved clinical trial.

The first has a long record. The mandatory national registry of the Swiss Blood Stem Cell Transplantation and Cellular Therapy group (SBST) holds data on 11,226 patients who received a blood stem cell transplant from 1997 to 2021, 4,031 with donor cells and 7,195 with their own (Passweg and colleagues, 2024). In 2024, according to Swiss Transfusion SRC, 336 blood stem cell transplants used cells from unrelated or related donors, and CAR T cell therapy was given 191 times in Switzerland.

The second has no comparable record. The International Society for Stem Cell Research (ISSCR) describes the list of conditions with proven stem cell treatments as very short, led by blood stem cell transplantation and grafts for some bone, skin and corneal injuries (ISSCR, nine things to know). The sections below cover Swiss law, the evidence, the risks and published prices.

The legal position: when stem cell therapy is legal in Switzerland

Two federal laws apply. The Transplantation Act of 8 October 2004, in force since 1 July 2007 and current in its consolidated version of 1 February 2021, covers the handling of human organs, tissues and cells and of the products obtained from them, which it calls transplant products. For transplant products it applies large parts of the Therapeutic Products Act of 15 December 2000 (in force since 1 January 2002, current version of 1 January 2025) and makes Swissmedic responsible for inspections.

The line is set out by Swissmedic, the Swiss regulator for therapeutic products. Cells that are not substantially processed and do the same job where they are put back as where they were taken count as an autologous transplant: anyone who prepares, stores or exports them must notify Swissmedic in advance, unless harvest, preparation and re-injection happen in the same operation. Cells that are substantially processed, for example expanded in culture or digested with enzymes, or that are used for a different function, are transplant products.

A transplant product may be used on a patient only if Swissmedic has authorised the product or its manufacturing process, or within a clinical trial Swissmedic has approved, and the firms that make or distribute it need a Swissmedic establishment licence. The regulator applies this expressly to stem cells used in aesthetic medicine, and it states that products containing human tissues or cells cannot be cosmetic products (Swissmedic, legal framework for tissues and cells). Clinical trials of therapeutic products need Swissmedic authorisation in advance under Article 54 of the Therapeutic Products Act.

The knee shows how the rules work in practice. Swissmedic treats fat-derived cells injected into a joint for arthritis as a transplant product even when they were prepared only mechanically, because a joint is not the tissue they came from. Products from umbilical cord tissue sit further out still: Swissmedic states that no clinical trial with such products has been approved in Switzerland and no product or manufacturing process authorised (Swissmedic, umbilical cord tissue).

Two further points complete the picture. A doctor may import a product that is not authorised in Switzerland for a defined patient, on the doctor's sole responsibility, but only if the conditions of Article 49 of the Medicinal Products Licensing Ordinance are met, among them that the product is authorised in a country with a comparable regulatory system. And fresh cell therapy, the injection of cells from calves or lambs, was never authorised by the Federal Office of Public Health or Swissmedic, which reported rulings against institutions offering it in June 2016.

Other countries draw similar lines. The US Food and Drug Administration, on a consumer page last updated in April 2024, states that the only stem cell products it has approved are blood-forming stem cells derived from umbilical cord blood, and that patients charged for other products outside a clinical trial are likely being offered them illegally. In December 2024 it also approved Ryoncil, a donor mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease.

Established and experimental uses of stem cells

Swiss basic insurance is a practical test of what counts as established, because the Federal Department of Home Affairs lists the treatments it must pay for and the conditions attached. Annex 1 of the Health Insurance Benefits Ordinance, edition of 1 July 2026, covers blood stem cell transplantation only in centres recognised by SBST and accredited by JACIE, the Joint Accreditation Committee of ISCT and EBMT, and names the diseases for which it pays.

The table also explains a common confusion. The ISSCR notes that doctors have transplanted blood stem cells for more than 50 years (ISSCR Guide to Stem Cell Treatments, February 2024). That record belongs to accredited transplant centres; it says nothing about cells injected into a knee or infused for ageing.

Stem cell therapy for knees: what the trials show

Cell injections have become a popular and costly option for knee osteoarthritis, as the authors of one large trial put it, and it is a use with a substantial body of randomised trials. A Cochrane review published on 2 April 2025, with evidence searched to 15 September 2023, included 25 randomised trials with 1,341 participants, 8 of which (459 participants) used a placebo injection for comparison. Against placebo, stem cell injections may slightly improve pain at six months, by 1.2 points on a 0 to 10 scale, and function, by 14.2 points on a 0 to 100 scale, in both cases on low-certainty evidence.

The reviewers were uncertain of the effects on quality of life and on the course of the disease; none of the included trials measured progression on X-ray. Serious adverse events were rare in both groups, 16 per 1,000 people with stem cells against 23 per 1,000 with placebo, but the reviewers judged the risk of other important harms, including those linked to cells that can promote growth or come from a donor, to be unknown.

A large head-to-head trial points the same way. In a randomised trial of 480 patients published in Nature Medicine in 2023, injections of bone marrow concentrate, fat-derived stromal vascular fraction or umbilical cord cells were no better at 12 months than a corticosteroid injection, and none of the four groups showed a significant change in the MRI score of the knee.

Guidelines have now drawn the conclusion. The American College of Rheumatology posted the summary of its 2026 osteoarthritis guideline on 14 September 2026. It strongly recommends against stem cell injections in knee and hip osteoarthritis, on moderate-certainty evidence, and strongly recommends against platelet-rich plasma as well. What it strongly recommends instead is exercise, weight loss for people with overweight or obesity, anti-inflammatory medicines and, for the knee and hip, glucocorticoid injections into the joint.

Ask any clinic that promises cartilage regrowth or a postponed knee replacement for the controlled trial that showed it. The same evidence applies to every clinic that offers these injections.

Risks, including those that are hard to see

A treatment with the patient's own cells involves two procedures, the harvest and the injection, and each carries its own risk. The ISSCR points out that cells taken out of the body can be contaminated with bacteria, viruses or other pathogens before they go back in, and that some clinics inject cells into places where they do not naturally belong.

The documented cases are serious. The US Food and Drug Administration lists blindness, tumour formation and infections among the adverse events reported after unapproved cell products. In 2017 the New England Journal of Medicine described three patients who developed severe loss of vision in both eyes after fat-derived cells were injected into their eyes at a US clinic, and in 2018 the US Centers for Disease Control and Prevention reported 12 patients hospitalised with infections after contaminated umbilical cord blood products were given for conditions such as pain.

Two further risks are less obvious. One is financial: the ISSCR notes that in most cases insurers and public health programmes do not pay for experimental treatments. The other is lost options: the ISSCR tells patients to ask whether an unproven treatment could exclude them from a later clinical trial or from other treatments.

What a first consultation and a procedure involve

A careful first consultation spends more time on your diagnosis and the product's regulatory status than on the procedure. The ISSCR expects a written consent form for any unproven treatment that states it is unproven and lists its specific risks, and a written protocol you can ask to see, including who approved it and when that approval expires.

Swiss clinics that store cells for later use

Some Swiss private clinics offer storage rather than treatment. Swiss Medical Network's website presents Swiss Stem Cells Solutions, which freezes lipoaspirate, the fat removed during liposuction, for later aesthetic or therapeutic use, and lists six sites: Klinik Bethanien in Zurich, Clinique Générale-Beaulieu in Geneva, Clinica Sant'Anna in Sorengo, Clinica Ars Medica in Gravesano, Clinique de Genolier and Hôpital de Saint-Imier. The site states that the service holds Swiss GMP certification and FACT-NetCord accreditation.

Clinica Ars Medica, 7 km north of Lugano, is described by Swiss Medical Network, the group it belongs to, as the reference centre in Ticino for orthopaedic surgery and traumatology.

Storage is not treatment. Whether frozen cells can later be used depends on the regulatory status of the eventual product, and the ISSCR warns that storing cells for an unproven future use can be costly, with no guarantee they will ever be usable.

What stem cell therapy costs

In Switzerland the established treatment is paid for by basic insurance: blood stem cell transplants for the listed diseases are covered in recognised centres, as the table of uses shows. For experimental cell treatments, the ISSCR notes that in most cases insurers and public health programmes do not pay.

The price below is the one the provider publishes itself, for a single bone marrow concentrate procedure.

Before comparing any offer, ask what is included and excluded, itemised, and what emergency care would cost if something went wrong, as the ISSCR recommends. For Swiss medical prices generally, see our note on what Swiss treatment costs, and for cell treatments sold within longevity programmes, our guide to longevity clinic prices in Switzerland.

Questions to ask a stem cell clinic

These questions draw on the ISSCR's patient guide and the Swiss rules above. Ask for the answers in writing.

If you are weighing an offer, we can put the published figures and options in our network in front of you, and we will say so when the better answer is treatment at home, as we explain in when Swiss treatment is not the answer. Write to us with the diagnosis and the offer you have received.

Sources

Laws are cited in the version in force on 22 September 2026. Prices are those providers published on that date; treat them as starting points, not quotations.